(Circulation. 1999;100:579-582.)
© 1999 American Heart Association, Inc.
Editorials |
New Insight Into the Role of Enhanced Adrenergic Receptor-Effector Coupling in the Heart
From the Cardiovascular Institute of the UPMC Health System, Pittsburgh, Pa.
Correspondence to Arthur M. Feldman, MD, PhD, Harry S. Tack Professor of Medicine, Director, Cardiovascular Institute of the UPMC Health System, 200 Lothrop St, S-572 Scaife Hall, Pittsburgh, PA 15213. E-mail feldmanam{at}msx.upmc.edu
Key Words: Editorials • receptors, adrenergic, beta • stress • heart failure • proteins
 |
Introduction |
|---|
 Top Introduction References |
|---|
The ability of the heart to augment the perfusion of vital organs and skeletal muscles during stress is predicated on its ability to increase contractility in response to adrenergic neurohormones that are released from postsynaptic nerve terminals within the heart and/or from the adrenal gland. These neurohormonal signals must then be detected and processed by a complex of proteins located within the sarcolemmal membrane, resulting in the conversion of the adrenergic signal to an alteration in the biomechanical properties of individual myocytes. This sarcolemmal protein complex consists of adrenergic receptors (ARs), guanine nucleotide–binding regulatory proteins, and the effector enzyme adenylyl cyclase. Myocardial contractility is augmented by the interaction of adrenergic agonists with ß1- and/or ß2-adrenergic receptors (ßARs) located on the surface of the sarcolemmal membrane (see review in Reference 11 ). These 2 ßAR subtypes are coupled to adenylyl cyclase activation by the stimulatory guanine nucleotide–binding protein (Gs). Interaction of the agonist-ßAR complex with the heterotrimeric G protein catalyzes the release of GDP from the
-subunit of the G protein (s), allowing the
binding of GTP and the subsequent activation of adenylyl cyclase by
s-GTP. This activation persists until
intrinsic GTPase activity of s hydrolyzes the
nucleotide, resulting in an inactive
s-GDP moiety.1
G-protein–mediated activation of adenylyl cyclase effects the
synthesis of the intracellular second messenger cAMP and the resulting
phosphorylation of a cAMP-dependent protein kinase
(PKA). Once phosphorylated, PKA is then able to effect
positive inotropic and chronotropic responses by phosphorylating a
group of intracellular proteins, including phospholamban, and the
L-type voltage-dependent calcium channel while at the same time
enhancing lusitropy via alterations in the sensitivity of troponin for
Ca2+. -Subunits of some G proteins also appear
to effect myocyte ion channel activity independent of adenylyl cyclase
activation and in so doing can also regulate myocyte function. In the human heart, activation of ß1-AR results in a marked increase in contractility. Furthermore, there is strong evidence that ß2-AR also couples to a positive inotropic response.2 A similar inotropic response is seen in neonatal but not adult rodent myocytes.3 However, investigators have recently suggested that ß2-ARs can regulate cardiac contractility independently of cAMP in both rodents and humans.4 Moreover, recent studies in murine myocytes demonstrate that ß2-AR couples to both Gs and the inhibitory guanine nucleotide–binding regulatory protein (Gi), resulting in an absence of inotropic responsiveness unless Gi is inhibited.5
As seen with many cellular pathways that impart critically important homeostatic control, the inotropic activity of the receptor–G-protein–adenylyl cyclase complex (RGC) is highly regulated. Indeed, in the presence of an agonist, there is a rapid waning of response due to desensitization of the RGC complex. This desensitization was initially attributed to sequestration within the cellular milieu; however, recent studies6 have demonstrated that an important component of receptor desensitization is phosphorylation of activated receptors by members of the G protein–coupled receptor kinase (GRK) family. ßAR kinase-1 (ßARK1: GRK2) is a GRK that specifically phosphorylates both ß1- and ß2-ARs when they are in the activated form, resulting in desensitization.7 8 Interestingly, regulation of ßARK expression is ligand induced: expression is significantly increased on exposure to agonist and substantially decreased in the presence of ß-adrenergic blockade.9 Although ßARK plays an important role in short-term desensitization, long-term exposure to agonists is associated with a decrease in the mRNA encoding the ßARs, a phenomenon that appears to be due at least in part to changes in mRNA stability.10 The activity of the RGC complex can also be modulated at the level of the G proteins. Changes at both the transcriptional and posttranslational levels can result in an alteration in either G-protein activity or stability.11 These changes in G-protein expression or function can be initiated by exposure to a variety of neurohormones, including catecholamines12 and proinflammatory cytokines.13
Although the heart depends on adrenergic drive to enhance function
during times of stress, investigators suggested that long-term exposure
to adrenergic drive might be maladaptive on the basis of the finding of
(1) a direct relationship between norepinephrine expression
and mortality14 and (2) an inability of the failing human
heart to appropriately augment myocardial contractility
in response to challenge with an adrenergic agonist.15
That alterations in ßAR-effector coupling are important in the
development of adrenergic insensitivity was first recognized when
investigators demonstrated that heart failure in humans was
characterized by a selective and nearly 50% downregulation of
ß1-AR.16 As a result of this
receptor downregulation, the ratio of
ß1:ß2-receptors was
shifted from 
80:20 in nonfailing heart to 60:40 in failing
ventricular myocardium. Subsequent studies
demonstrated that this downregulation was related to a decrease in
ß1-receptor mRNA17 and could be
initiated by exposure to adrenergic agonists.18 However,
heart failure in humans was also associated with other substantive
changes in the RGC complex, including uncoupling of
ß2-AR from adenylyl cyclase, increased
functional activity of Gi, and enhanced
expression of ßARKs.19
Although downregulation of RGC coupling was associated with diminished contractile response, investigators proposed that enhanced exposure to catecholamines could be cardiotoxic, and thus, receptor downregulation might be an adaptive rather than a maladaptive phenomenon. This hypothesis was based on the recognition of an inverse relationship between norepinephrine levels and survival in patients with congestive heart failure (CHF).14 Additional support for this hypothesis comes from laboratory data demonstrating the ability of catecholamines to negatively affect the biology and structure of the myocyte, as evidenced by downregulation of adrenergic signaling systems, stimulation of apoptosis in adult rat ventricular myocytes in vivo, and myofibrillar degeneration.20 Furthermore, despite favorable hemodynamic effects, endogenous production of catecholamines, as occurs in some disease states and with stress,21 can be cardiotoxic in humans, and the therapeutic use of ß-adrenergic agonists has been shown to accelerate disease progression and shorten life expectancy in patients with heart failure. Most importantly, both selective and nonselective ß-blockade has provided salutary effects on morbidity and mortality in patients with CHF,22 presumably due to reversal of intrinsic systolic dysfunction via a time-dependent biological effect on the myocardium. Interestingly, recent studies have demonstrated the presence of autoantibodies directed against ß1-AR in some patients with dilated cardiomyopathy. In vitro, these autoantibodies can enhance myocardial contractility but also downregulate adrenergic receptors after longer-term treatment. Thus, even in the absence of enhanced adrenergic drive, immune-mediated alterations in receptor-effector coupling might precipitate the development of cardiac failure.
To better understand the role of the many components of the RGC complex in cardiovascular homeostasis, investigators have recently taken advantage of transgenic technology that has been developed over the past decade. In studies evaluating the RGC complex, transgenic manipulation of various components provides the novel opportunity to enhance or impede signaling in an agonist- or antagonist-independent manner. Not surprisingly, overexpression of ß2-AR resulted in increased basal myocardial adenylyl cyclase activity, enhanced atrial contractility, and increased left ventricular function in vivo, changes that were consistent with those seen in wild-type animals maximally stimulated with the adrenergic agonist isoproterenol.23 However, transgenic mice overexpressing ß2-AR also demonstrated maximal enhancement of myocardial relaxation due to a selective decrease in the amount of phospholamban protein, a constitutive inhibitor of sarcoplasmic reticulum Ca2+-ATPase activity.24 Consistent with the results in studies of mice overexpressing ß2-AR, transgenic mice overexpressing a ßARK inhibitor (and therefore having enhanced ß1-AR and ß2-AR effector enzyme coupling) also demonstrated increased myocardial contractility.7 Mice overexpressing ßARK demonstrated attenuation of isoproterenol-stimulated myocardial contractility, diminished myocardial adenylyl cyclase activity, and uncoupling of ßARs from downstream signal-transduction pathways when the levels of ßARK overexpression were similar to those seen in failing human hearts.7 Importantly, neither the mice overexpressing ß2-AR nor those overexpressing the ßARK inhibitor developed abnormalities in myocardial function or morphology despite the heightened adrenergic signaling.
In this issue of Circulation,25 Akhter and colleagues present an elegant study that provides additional evidence that supports the role of ßARK in heart muscle adrenergic responsiveness and more importantly suggests that ßARK might provide a novel target for future therapeutic strategies. Using the heart as an "in vivo reaction vessel," Akhter et al created hybrid transgenic mice harboring cardiac-specific overexpression of both ßARK and a ßARK inhibitor (ßARKct peptide). The coexpression of ßARKct inhibited both the elevated myocardial ßARK1 activity as well as the abnormal ßAR responsiveness that characterized mice overexpressing only ßARK. Thus, ßARKct effectively normalized both the biochemical and physiological pathology effected by ßARK overexpression. Several other technologies could putatively have been used to address a similar question. For example, inhibitor proteins or dominant negatives could be overexpressed by driving gene expression with an adenoviral vector, or alternatively, pharmacological inhibitors could be used to selectively inhibit a known protein. However, both of these techniques have marked limitations. Adenoviruses may be rapidly cleared by immunologic reactions, allowing only a limited window in which to study the effects of gene overexpression. In addition, gene-transfer techniques effect changes in only a subpopulation of myocytes. Pharmacological inhibitors, if available, often lack specificity or have ancillary properties that abrogate accurate interpretation of results. Therefore, the novel technique used in the report by Akhter et al provides a mechanism for persistently and selectively abrogating the effects of ßARK overexpression in vivo and confirms the hypothesis that ßARK might provide a new therapeutic target. As noted by Akhter et al, additional support for a role for ßARK inhibition in the therapy of CHF comes from recent studies in which the hybrid transgenic mouse technique was used to overexpress ßARKct in a line of cardiomyopathic mice harboring mutations in the gene encoding the muscle-specific LIM protein MLP (MLP -/-).26 Overexpression of ßARKct rescued the myopathic phenotype in these transgenic mice, which, like the ßARK transgenic mice, demonstrated increases in ßARK1 levels consistent with those found in failing human heart.
Although the study by Akhter et al25 suggests that
positive modulation of adrenergic receptor coupling and, in particular,
inhibition of ßARK1 expression might have salutary effects in
patients with CHF, transgenic modulation of other components of the RGC
complex have resulted in the development of a different
phenotype. For example, overexpression of
Gs in transgenic mice, resulting in a 2.8-fold
increase in Gs protein, was reported to
enhance the rate of adenylyl cyclase activation and the relative number
of ßARs that bound agonist with high affinity without
affecting myocardial morphology.27 However, subsequent
studies by the same investigators using older mice (10 months of
age) demonstrated normal baseline contractility but an
enhanced response to isoproterenol. Furthermore, in 16-month-old mice,
pathological and histological analyses revealed
cellular hypertrophy, degeneration, atrophy, and
replacement fibrosis.28 Moreover, ECG monitoring
demonstrated a high incidence of arrhythmias with increased
mortality compared with control mice.29 Indeed, in the
older mice, left ventricular ejection fraction was markedly
diminished, left ventricular end-diastolic
dimension was increased, and baseline heart rates were elevated
compared with wild-type controls. Recently, transgenic technology has
also been used to create mice overexpressing the human
ß1-AR.30 At a young age (4 to 5
months), these mice display myocardial remodeling with myocyte
hypertrophy and interstitial replacement
fibrosis. However, by 8 months of age, they demonstrate marked
increases in left ventricular end-systolic and
end-diastolic dimensions consistent with
development of a dilated
cardiomyopathy.31 Thus, although
overexpression of ß2-AR or enhanced
ß2-AR activity via overexpression of a ßARK
inhibitor improves left ventricular
performance without compromising the normal cardiac
morphological phenotype, enhanced expression of other
components of the RGC complex has deleterious effects that result in a
transition from the wild type to a myopathic phenotype.
The disparate results seen in these transgenic mice overexpressing the various components of the RGC complex raise obvious questions about the physiological effects of RGC pathway inhibition and stimulation in mice. Moreover, they raise interesting questions about the difference between mice and humans and suggest that the RGC complex and its regulation may be far more complex than originally realized. At the clinical level, it appears that ß-blockade is beneficial in patients with CHF, whereas ß-stimulation is deleterious. However, studies of transgenic mice provide a confusing array of results. Activation of ß2-ARs and inhibition of ßARK provide beneficial effects, whereas stimulation of other RGC complex moieties is clearly harmful. Although the origin of these marked differences remains undefined, several explanations might be speculated: (1) differences in the ratios of receptor subtypes in humans and rodents; (2) the presence of unique and undefined substrates for the ßARK2 inhibitor; (3) the potential relevance of the recently identified ß3-AR and its possible uncoupling by ßARK; (4) differences between ß2-AR coupling with Gi and Gs in human and murine hearts; and (5) the possibility that the beneficial effects of ß-blockade are due to cellular mechanisms independent of the ß1-AR or ß2-AR. Interestingly, the latter possibility is supported by a recent study that has suggested that the benefits of the ß-blocker carvedilol are inversely correlated with norepinephrine levels in patients with CHF.32 In addition, genetic factors that alternatively regulate the various proteins of the RGC complex might play a role in the response of a specific individual to enhance adrenergic drive.
In summary, the marked disparities in phenotype that result after overexpression of the various components of the RGC complex have raised interesting questions regarding the biology and pathophysiology of the RGC complex. Although we must learn more about the intricacies of cardiac signal transduction, the elegant hybrid transgenic technique described by Akhter et al25 in this issue of Circulation should provide the technology with which investigators can address these important questions.
|
Footnotes |
|---|
The opinions expressed in this editorial are not necessarily those of the editors or of the American Heart Association.
|
References |
|---|
|
TopIntroductionReferences |
|---|
1. Levitzki A. From epinephrine to cyclic AMP. Science. 1988;241:800–806.
2.
Fowler MB, Laser JA, Hopkins GL, Minobe W, Bristow MR.
Assessment of the ß-adrenergic receptor pathway in the intact
failing human heart: progressive receptor downregulation and
subsensitivity to agonist response. Circulation. 1986;74:1290–1301.
3.
Kuznetsov V, Pak E, Robinson RB, Steinberg SF.
ß2-adrenergic receptor actions in neonatal and adult rat
ventricular myocytes. Circ Res. 1995;76:40–52.
4.
Altschuld RA, Starling RC, Hamlin RL, Billman GE,
Hensley J, Castillo L, Fertel RH, Hohl CM, Robitaille P-ML, Jones LR,
Xiao RP. Response of failing canine and human heart cell to
ß2-adrenergic stimulation.
Circulation. 1995;92:1612–1618.
5.
Xiao RP, Avdonin P, Zhou YY, Cheng H, Akhter SA,
Eschenhagen T, Lefkowitz RJ, Koch WJ, Lakatta EG. Coupling of
ß2-adrenoceptor to Gi
proteins and its physiological relevance in murine
cardiac myocytes. Circ Res. 1998;84:43–52.
6.
Benovic JL, Strasser RH, Caron MG, Lefkowitz RJ.
ß-Adrenergic receptor kinase: identification of a novel protein
kinase that phosphorylates the agonist-occupied form of the
receptor. Proc Natl Acad Sci U S A. 1986;83:2797–2801.
7.
Koch WJ, Rockman HA, Samama P, Hamilton R, Bond RA,
Milano CA, Lefkowitz RJ. Cardiac function in mice overexpressing
the ß-adrenergic receptor kinase or a ßARK
inhibitor. Science. 1995;268:1350–1353.
8.
Freedman NJ, Liggett SB, Drachman DE, Pei G, Caron MG,
Lefkowitz RJ. Phosphorylation and desensitization of
the human ß-adrenergic receptor: involvement of G
protein-coupled receptor kinases and cAMP-dependent protein kinase.
J Biol Chem. 1995;270:17953–17961.
9.
Iaccarino G, Tomhave ED, Lefkowitz RJ, Koch WJ.
Reciprocal in vivo regulation of myocardial G protein-coupled receptor
kinase expression by ß-adrenergic receptor stimulation and
blockade. Circulation. 1998;98:1783–1789.
10.
Pende A, Tremmel KD, DeMaria CT, Blaxall BC, Minobe WA,
Sherman JA, Bisognano JD, Bristow MR, Brewer G, Port JD. Regulation of
the mRNA-binding protein AUF1 by activation of the ß-adrenergic
receptor signal transduction pathway. J Biol Chem. 1996;271:8493–8501.
11.
Mumby SM, Heukeroth RO, Gordon JI, Gilman AG.
G-protein -subunit expression, myristoylation, and membrane
association in COS cells. Proc Natl Acad Sci U S A. 1990;87:728–732.
12.
Reithmann C, Gierschik P, Sidiropoulos D, Werdan K,
Jakobs KH. Mechanism of noradrenaline-induced heterologous
desensitization of adenylate cyclase stimulation in rat
heart muscle cells: increase in level of inhibitory
G-protein -subunits. Eur J Pharmacol. 1989;172:211–221.[Medline]
[Order article via Infotrieve]
13.
Gulick T, Chung MK, Pieper SJ, Lange LG, Schreiner GF.
Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte
ß-adrenergic responsiveness. Proc Natl Acad Sci U S A. 1989;86:6753–6757.
14. Cohn JN, Levine B, Olivari MT, Garberg V, Lura D, Francis GS, Simon AB, Rector T. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med. 1984;311:819–823.[Abstract]
15. Ginsburg R, Bristow MR, Billingham ME, Stinson EB, Schroeder J, Harrison DC. Study of the normal and failing isolated human heart: decreased response of failing heart to isoproterenol. Am Heart J. 1983;106:535–540.[Medline] [Order article via Infotrieve]
16.
Bristow MR, Ginsburg R, Umans V, Fowler M, Minobe W,
Rasmussen R, Zera P, Menlove R, Shah P, Jamieson S.
ß1- and
ß2-adrenergic-receptor subpopulations in
nonfailing and failing human ventricular
myocardium: coupling of both receptor subtypes to muscle
contraction and selective ß1-receptor
down-regulation in heart failure. Circ Res. 1986;59:297–309.
17. Bristow MR, Minobe WA, Raynolds MV, Port JD, Rasmussen R, Ray PE, Feldman AM. Reduced ß1 receptor messenger RNA abundance in the failing human heart. J Clin Invest. 1993;92:2737–2745.
18.
Brodde OE, Daul A, Michel-Reher M, Boomsma F, Man in't
Veld A, Schlieper P, Michel MC. Agonist-induced desensitization of
ß-adrenoceptor function in humans: subtype-selective reduction in
ß1- or
ß2-adrenoceptor-mediated
physiological effects by Xamoterol or Procaterol.
Circulation. 1990;81:914–921.
19. Feldman AM. Modulation of adrenergic receptors and G-transduction proteins in failing human ventricular myocardium. Circulation. 1993;87(suppl IV):IV-27–IV-34.
20.
Mann DL, Kent RL, Parsons B, Cooper G. Adrenergic
effects on the biology of the adult mammalian cardiocyte.
Circulation. 1992;85:790–804.
21.
White M, Wiechmann RJ, Roden RL, Hagan MB, Wollmering
MM, Port JD, Hammond E, Abraham WT, Wolfel EE, Lindenfeld J, Fullerton
D, Bristow MR. Cardiac ß-adrenergic neuroeffector systems in
acute myocardial dysfunction related to brain injury.
Circulation. 1995;92:2183–2189.
22. Eichhorn EJ, Bristow MR. Medical therapy can improve the biological properties of the chronically failing heart. Circulation. 1996;949:2285–2296.
23.
Milano CA, Allen LF, Rockman HA, Dolber PC, McMinn TR,
Chien KR, Johnson TD, Bond RA, Lefkowitz RJ. Enhanced myocardial
function in transgenic mice overexpressing the
ß2-adrenergic receptor. Science. 1994;264:582–586.
24. Rockman HA, Hamilton R, Jones LR, Milano CA, Mao L, Lefkowitz RJ. Enhanced myocardial relaxation in vivo in transgenic mice overexpressing the ß2-adrenergic receptor is associated with reduced phospholamban protein. J Clin Invest. 1996;97:1618–1623.[Medline] [Order article via Infotrieve]
25.
Akhter SA, Eckhart AD, Rockman HA, Shotwell K,
Lefkowitz RJ, Koch WJ. In vivo inhibition of elevated
myocardial ß-adrenergic receptor kinase activity in hybrid
transgenic mice restores normal ß-adrenergic signaling and function.
Circulation. 1999;100:648-653.
26.
Rockman HA, Chien KR, Choi DJ, Iaccarino G, Hunter JJ,
Ross J Jr, Lefkowitz RJ, Koch KM. Expression of a ß-adrenergic
receptor kinase 1 inhibitor prevents the development of
myocardial failure in gene-targeted mice. Proc Natl Acad Sci
U S A. 1998;95:7000–7005.
27.
Gaudin C, Ishikawa Y, Wright D, Madavi V, Nadal-Ginard
B, Wagner TE, Vatner DE, Homcy CJ. Overexpression of
Gs protein in the hearts of transgenic mice.
J Clin Invest. 1995;95:1676–1686.
28.
Iwase M, Bishop SP, Uechi M, Vatner DE, Shannon RP,
Kudej RK, Wight DC, Wagner TE, Ishikawa Y, Homcy CJ, Vatner SF. Adverse
effects of chronic endogenous sympathetic drive induced by
cardiac Gs overexpression. Circ
Res. 1996;78:517–524.
29.
Iwase M, Uechi M, Vatner DE, Asai K, Shannon RP, Kudej
RK, Wagner TE, Wight DC, Patrick TA, Ishikawa Y, Homcy CJ, Vatner SF.
Cardiomyopathy induced by cardiac
Gs overexpression. Am J
Physiol. 1997;272:H585–H589.
30. Bisognano JD, Pende A, Tremmel KD, Dutcher DL, Knudson OA, Bohlmeyer TJ, Bristow MR, Port JD. Preliminary characterization of a transgenic mouse overexpressing the human ß1 adrenergic receptor. J Investig Med. 1997;45:210A. Abstract.
31. Port JD, Weinberger JD, Bisognano JD, Knudson TJ, Bohlmeyer TJ, Pende A, Bristow MR. Echocardiographic and histopathological characterization of young and old transgenic mice over-expressing the human ß1-adrenergic receptor. J Am Coll Cardiol. 1998;31:177. Abstract.
32.
Richards AM, Doughty R, Nicholls MG, Macmahon S, Ikram
H, Sharpe N, Espiner EA, Frampton C, Yandle TG, for the Australia-New
Zealand Heart Failure Group. Neurohumoral prediction of benefit from
carvedilol in ischemic left ventricular
dysfunction. Circulation. 1999;99:786–792.
This article has been cited by other articles:
 |
|
 |
|
  X. P. Yi, A. M. Gerdes, and F. Li Myocyte Redistribution of GRK2 and GRK5 in Hypertensive, Heart-Failure-Prone Rats Hypertension, June 1, 2002; 39(6): 1058 - 1063. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. A Nikolaidis, T. Hentosz, A. Doverspike, R. Huerbin, C. Stolarski, Y.-T. Shen, and R. P Shannon Catecholamine stimulation is associated with impaired myocardial O2 utilization in heart failure Cardiovasc Res, February 1, 2002; 53(2): 392 - 404. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. J. Lefkowitz, H. A. Rockman, and W. J. Koch Catecholamines, Cardiac {beta}-Adrenergic Receptors, and Heart Failure Circulation, April 11, 2000; 101(14): 1634 - 1637. [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||